🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer

RecruitingNAAges any - anyAllUniversity College, London
NCT07135271 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer. The main question it aims to answer is: • Does the Bespoke Decision Support tool reduce decisional conflict in those choosing between treatment options for localised prostate cancer? Researchers will compare the addition of the Bespoke Decision Support tool to standard treatment counselling versus standard counselling alone. Patient participants will: * Receive standard counselling with or without access to the Bespoke Decision Support tool (based on arm of randomisation), prior to making a treatment decision. * Answer to questionnaires regarding urinary, sexual and bowel function and decision-making outcomes before and after making a treatment decision and at 3, 6, and 12 months af

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria for Patient-Participants: 1. Newly diagnosed localised prostate cancer 2. Clinically suitable for at least two of the following treatment options: 1. active surveillance 2. focal therapy 3. radical prostatectomy 4. external beam radiotherapy 3. Willing and able to provide informed consent Exclusion Criteria for Patient Participants: 1. Unsuitable for active treatment due to very low risk prostate cancer or significant health issues. 2. Suspicion of metastatic prostate cancer based on clinical or imaging evidence including: 1. Imaging identified suspicious lesion on bone scan, CT, whole-body MRI or PSMA-PET/CT; 2. PSA ≥50 ng/mL. 3. Not able to provide informed consent. 4. Insufficient English proficiency for adequate use of BeSpoke Decision Support. (Patients with support from a family member, friend or partner, to overcome lack of English proficiency will be included.) 5. Enrolled in other localised prostate cancer studies where treatment is assigned rather than chosen by participants, e.g. PART Trial (Partial prostate Ablation vs Radical prostaTectomy) Inclusion criteria for Health Care Professionals: 1. Have seen BeSpoke Decision Support and spoken to patients in the intervention arm. 2. Willing and able to provide written or electronic informed consent Exclusion criteria for Health Care Professionals 1\. No experience of BeSpoke Decision Support.
💊

What it tests

  • Bespoke Decision Support tool
  • Standard of Care (SOC) decision support material
📍

Where

1 site
University College London Hospitals NHS Foundation Trust
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy